CPX-351 in <i>FLT3</i>-mutated acute myeloid leukemia.

Front Oncol · 2023 · PMC10691756 · PMID 38044999

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, post-hoc subgroup analysis showed a trend toward improved OS with CPX-351 vs. 7 + 3 in patients with FLT3 mutations (median OS = 10.25 months vs. 4.60 months; HR = 0.76; 95% CI = 0.34–1.66), although caution should be exerted when interpreting these data due to the small number of patients with baseline FLT3 mutations included in this analysis.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.